U.S. Jennerex announces positive Phase I clinical results on JX-594

The U.S. Jennerex Biotherapeutics said on October 23 that its lead product candidate JX-594, a genetically-engineered vaccinia virus strain, demonstrated objective evidence of efficacy in 10 of the 13 evaluable Korean patients with advanced treatment-refractory tumors in the liver (primary and metastatic), according to Green Cross.

Green Cross signed an agreement with Jennerex Biotherapeutic...